Sharemaestro Newsreel

Citius Oncology's LYMPHIR has 44 ordering institutions, 383 July vials

Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Estimates By $0.68 EPS

Adlai Nortye (NASDAQ:ANL) Announces Earnings Results

LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have reported a beneficial ownership of 5.0% in LB Pharmaceuticals Inc. (LBRX), totaling 1,447,310 shares, through an amended Schedule 13G filing. This ownership percentage is based on 28,676,652 shares outstanding as …

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Orchestra BioMed (OBIO) director withholds 3,761 shares to cover RSU tax bill

Orchestra BioMed (OBIO) director has 4,885 shares withheld for RSU tax

XWELL (XWEL) doubles loss yet lifts equity with $31.3M raise and asset sale plan

OnKure Therapeutics (OKUR) investor BVF discloses 8% stake plus 2.15M pre-funded warrants

Orchestra BioMed (OBIO) director reports 4,238 RSU tax-withholding shares

Femasys Reports $331,827 Q2 Revenue and $4.47 Million Net Loss

Femasys (FEMY) reported a Q2 2026 revenue of $331,827, an 18.9% decrease year-over-year, and a net loss of $4.47 million. Despite the revenue decline, the company completed a $30 million private placement and launched FemaSeed Complete, while insiders made multiple stock purchases, indicating confidence …

BullFrog AI Holdings (BFRG) posts Q2 2026 loss, flags going concern and Nasdaq risks

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed investors. However, Vertex has always bounced back, and it recently hit a new all-time high, though it has since …

NeoGenomics (NEO) stake tops 8% for First Light’s Mathew Arens

Mathew P. Arens and First Light Asset Management, LLC have reported their beneficial ownership in NeoGenomics, Inc. through a Schedule 13G/A filing. Arens beneficially owns 8.37% of NeoGenomics' common stock, totaling 10,759,586 shares, which includes holdings through First Light, direct shares, and a joint …

VSee Health (VSEE) cuts debt, gains on asset sale but flags going concern risk

LeonaBio (LONA) loss widens as cash burn rises and going concern risk emerges

Nephros (NEPH) director Arthur Amron granted 2,418 shares, holds 140,874

Nephros Inc. director Arthur H. Amron was granted 2,418 shares of Common Stock on August 12, 2026, as compensation for his board service, increasing his direct holdings to 140,874 shares. He also holds stock options for 7,323 shares fully vested at an exercise price …

NewAmsterdam Pharma (NAMS) hires Robert Gunning as new principal accounting officer

NewAmsterdam Pharma Company N.V. (NAMS) has appointed Robert W. Gunning, 55, as its new principal accounting officer, effective August 10, 2026. Gunning will receive an annual base salary of $375,000, a target annual performance bonus of 30% of his base salary, and equity awards …

NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal

NewAmsterdam Pharma (NAMS) has filed an amendment detailing the separation and advisory agreements with its former Chief Operating Officer, Douglas Kling, who resigned effective August 14, 2026. Kling's unvested stock options and restricted stock units will be canceled, except for those tied to continued …

Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing

Vestal Point Capital, LP and its Chief Investment Officer Ryan Wilder have disclosed a 6.1% stake in Myriad Genetics, Inc. (MYGN) through a Schedule 13G filing. The reporting group beneficially owns 5,735,000 shares of common stock, representing 6.1% of the 94,448,210 outstanding shares as …

Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE

Jasper Therapeutics (JSPR) reported a significantly narrowed net loss of $2.8 million in Q2 2026, down from $26.7 million in Q2 2025, largely due to lower operating expenses and substantial other income. The company also announced the completion of its acquisition of Kira Pharmaceuticals …

Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund

Point72 Asset Management and its related entities, including Point72 Capital Advisors, Inc. and Steven A. Cohen, have reported a beneficial ownership of 1,993,837 shares of Janux Therapeutics (JANX) common stock, representing 3.3% of the outstanding class as of June 30, 2026. This stake is …

Iovance Biotherapeutics stock hits 52-week high at 6.94 USD

Iovance Biotherapeutics (IOVA) stock reached a 52-week high of $6.94, marking a 167% increase over the past year and reflecting significant market optimism. The company reported strong Q2 2026 earnings, surpassing Wall Street expectations with revenue of $99.31 million and a narrower-than-anticipated adjusted loss, …

Quoin Q2 Loss Hits $5.37 Million as FDA Clears Peeling Skin IND

Quoin Pharmaceuticals Ltd. (QNRX) reported a net loss of $5.37 million for the second quarter of 2026, an increase from $3.70 million in the prior year. Despite this, the company's cash position is expected to fund operations into 2027. The FDA also conditionally approved …

Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition

Curis: Q2 Earnings Snapshot

Curis Inc. (CRIS) reported a second-quarter loss of $8.6 million, which translates to a loss of $4.02 per share. This information was generated by Automated Insights using data from Zacks Investment Research.

Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside

Satellos Bioscience Inc.'s average 12-month price target has been adjusted to $21.78, down from $22.04, according to estimates from 6 analysts. This new target suggests a potential upside of approximately 122% from the August 13 closing price. The consensus rating among 7 covering analysts …

Satellos Bioscience (MSLE) enters $50M at-the-market share deal

Satellos Bioscience Inc. (MSLE) has established an at-the-market (ATM) equity offering program, allowing it to sell up to $50 million of its common shares through Leerink Partners LLC. This program operates under an existing shelf registration of up to $300 million and provides Satellos …

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., August 14, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate …

ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130

Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake

Point72 entities, including Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen, have reported a 7.6% beneficial stake in Atara Biotherapeutics (ATRA). This stake, totaling 687,718 shares of common stock, is held by Point72 Associates, LLC, an investment fund managed by …

Baker Bros. cuts Cerus Corporation (CERS) position to 3.2% ownership stake

Baker Bros. Advisors LP and related reporting persons have filed an Amendment No. 13 indicating a reduction in their beneficial ownership of Cerus Corporation (CERS) common stock to 3.2%. This ownership comprises 6,395,431 shares held by Baker Brothers Life Sciences, L.P. and 667, L.P., …

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG

This article announces that QIAGEN N.V. has received a notification from the AFM (the Netherlands Authority For the Financial Markets) regarding a voting rights announcement. Wellington Management Group LLP reported a transaction on August 12, 2026, indicating they hold 4.96% of the voting rights …

Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing

Femasys Inc. (NASDAQ: FEMY) reported a narrowed net loss for the first half of 2026, totaling $3,622,995, a significant improvement from $10,482,761 in the prior-year period. The company also announced the completion of a $30 million private placement, which is expected to strengthen its …

Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A

Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …

Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss

Jasper Therapeutics (JSPR) announced a net loss of $2.8 million for the second quarter ended June 30, 2026. The company recently acquired Kira Pharmaceuticals, raising approximately $132 million, and anticipates releasing interim data and making regulatory filings for its expanded pipeline assets in late …